| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 8 | 8 | 8 | 8 | 8 | 8 | 6 | 7 | 7 | 7 | 7 | 6 |
| Expenses | 7 | 8 | 8 | 8 | 7 | 7 | 6 | 6 | 7 | 7 | 6 | 6 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit % | 6 % | 6 % | 5 % | 5 % | 5 % | 4 % | 5 % | 8 % | 9 % | 8 % | 8 % | 7 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Tax | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| EPS in ₹ | 0.21 | 0.21 | 0.40 | 0.65 | 0.34 | -0.01 | 0.45 | 0.74 | 1.82 | 1.93 | 1.97 | 1.80 |
Colinz Laboratories
Colinz Laboratories
40.00
+0.09
(0.23%)
There are 2 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
18.20 Cr
EPS
1.97
PE Ratio
39.60
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
88.70
52 Week Low
37.40
PB Ratio
1.53
Debt to Equity
0.07
Sector
Pharmaceuticals Actual
Company News
View All News
Colinz Laboratories announced the death of Dr. Mani L.S., a Non-Executive Director, and appointed Mrs. Vijaya Mani as Additional Non-Executive Director effective November 11, 2025, subject to shareholder approval. The Board expressed condolences for Dr. Mani L.S., acknowledging his leadership and guidance to the company. Following these changes, the company reconstituted its board committees including Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, and Risk Management Committee, with Mrs. Vijaya Mani serving as Chairman of the Risk Management Committee. The appointments comply with SEBI regulations, and Mrs. Vijaya Mani has not been debarred from holding director positions.
Dr. Mani L.S., Founder Director, Company Secretary, and Compliance Officer of Colinz Laboratories Limited, passed away on November 7, 2025. He ceased to hold office as Director (non-Executive), Company Secretary, and Compliance Officer with effect from November 7, 2025, and his membership in all Board Committees also ended. The company described him as a guiding force and principal architect behind the company's vision and values. Colinz Laboratories is taking steps to identify and appoint a qualified Company Secretary to fill the vacancy. In the interim, Chief Financial Officer Mr. Ganesh Chitte will oversee compliance and regulatory functions.
Colinz Laboratories Reports Quarterly Financial Results for Period Ended September 30, 2025
9 days ago
9 days agoColinz Laboratories Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The pharmaceutical formulations manufacturer reported revenue from operations of Rs. 138.80 lakhs for the quarter, compared to Rs. 156.61 lakhs in the previous quarter. Net profit for the quarter stood at Rs. 14.05 lakhs versus Rs. 11.92 lakhs in the prior quarter. For the half year, revenue from operations reached Rs. 295.41 lakhs with net profit of Rs. 25.97 lakhs. The company's total assets increased to Rs. 1,212.62 lakhs as of September 30, 2025, from Rs. 1,181.74 lakhs in March 2025. Cash and cash equivalents stood at Rs. 742.18 lakhs. The results were reviewed by the audit committee and approved by the board of directors. Vora Associates, the company's statutory auditors, issued an unqualified review report on the financial statements.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,732.10 | #1 4,11,749.90 | 39.63 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 66.26 | |
6,520.00 | 1,73,603.20 | 69.64 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.59 | |
3,824.60 | 1,29,482.50 | 60.46 | 11,539.40 | 6.99 | 1,911 | 30.46 | 70.50 | |
1,519.30 | 1,22,366.70 | 22.59 | 28,409.50 | 7.12 | 5,291 | 3.71 | 44.46 | |
1,229.60 | 1,01,113.50 | #1 17.88 | 33,741.20 | 16.73 | 5,725 | -0.38 | 47.35 | |
951.40 | 94,475.30 | 19.03 | 23,511.00 | 18.55 | 4,615 | 34.60 | 39.39 | |
2,270.00 | 91,653.00 | 52.89 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 32.59 | |
2,033.90 | 90,250.10 | 21.39 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 62.84 | |
5,767.50 | 68,110.20 | 29.54 | 13,458.30 | 3.70 | 2,216 | 21.39 | 70.49 | |
1,183.60 | 67,849.20 | 20.35 | 32,345.60 | 9.43 | 3,484 | 3.81 | 67.18 |
Growth Rate
Revenue Growth
-6.85 %
Net Income Growth
-
Cash Flow Change
-240.78 %
ROE
-3.68 %
ROCE
-8.54 %
EBITDA Margin (Avg.)
3.75 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 11 | 10 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 11 | 12 |
| Fixed Assets | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Current Assets | 6 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 9 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Other Assets | 8 | 7 | 7 | 7 | 7 | 6 | 8 | 7 | 8 | 9 | 9 |
| Total Liabilities | 11 | 10 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 11 | 12 |
| Current Liabilities | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 |
| Non Current Liabilities | 3 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 10 |
| Reserve & Surplus | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 7 |
| Share Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1 | -0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | -2 |
| Investing Activities | 0 | 0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 |
| Operating Activities | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 1 | -2 |
| Financing Activities | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Apr 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 36.42 % | 36.42 % | 36.41 % | 36.41 % | 36.38 % | 66.01 % | 66.01 % | 65.93 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % | 66.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.07 % | 0.07 % | 0.00 % | 0.07 % | 0.07 % | 0.12 % | 0.12 % | 0.12 % | 0.12 % | 0.12 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 60.14 % | 59.76 % | 59.89 % | 59.83 % | 59.92 % | 31.83 % | 31.81 % | 31.84 % | 31.80 % | 31.88 % | 32.00 % | 31.51 % | 31.54 % | 31.09 % | 30.95 % | 31.04 % | 31.01 % | 30.44 % | 31.04 % | 30.97 % |
| Others | 3.38 % | 3.76 % | 3.70 % | 3.69 % | 3.64 % | 2.05 % | 2.07 % | 2.11 % | 2.07 % | 2.00 % | 2.00 % | 2.49 % | 2.45 % | 2.91 % | 3.05 % | 2.96 % | 2.99 % | 3.56 % | 2.95 % | 3.03 % |
| No of Share Holders | 0 | 2,146 | 2,279 | 2,421 | 2,607 | 2,821 | 2,639 | 2,646 | 2,794 | 2,863 | 2,825 | 2,873 | 2,915 | 2,929 | 2,980 | 3,116 | 3,202 | 3,216 | 3,238 | 3,272 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 63.22 | 58.00 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 54.99 | 57.52 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 59.95 | 57.93 |
| 16 May 2025 | Quarterly Result Announcement | NA | 16 May 2025 | 50.63 | 57.50 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 40.19 | 45.31 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 45.31 | 43.11 |
| 03 Nov 2025 | Quarterly Result Announcement | NA | 03 Nov 2025 | 42.35 | 41.53 |
Announcements
Intimation Regarding Appointment Of Additional Director (Non-Executive Non-Independent Director.)1 day ago
1 day agoBoard Meeting Outcome for Outcome Of The Board Meeting1 day ago
1 day agoBoard Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations 2015.4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Demise4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication8 days ago
8 days agoFIANACIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30-9-20259 days ago
9 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.9 days ago
9 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.9 days ago
9 days agoBoard Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations 2015.Oct 25, 2025
Oct 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 16, 2025
Oct 16, 2025DISCLOSURE UNDER REGULATION 30 AND 37AOct 14, 2025
Oct 14, 2025Postal Ballot NoticeOct 14, 2025
Oct 14, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotOct 14, 2025
Oct 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 11, 2025
Oct 11, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotOct 04, 2025
Oct 04, 2025Non Applicability Under Regulation 32 Of SEBI (LODR) Regulation2015 For The Quarter Ended On 30-9-2025Oct 03, 2025
Oct 03, 2025Non-Applicability Of Related Party Transactions Under Regulation 23(9) For The 30Th Sep-2025Oct 03, 2025
Oct 03, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Sep 30, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Aug 30, 2025Reg. 34 (1) Annual Report.Aug 28, 2025
Aug 28, 2025BOOK CLOSURE FOR THE 39TH AGM OF M/S COLINZ LABORATORIES LTDAug 26, 2025
Aug 26, 202539Th AGM NOTICE AND BOOK CLOSUREAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025RESULTS FOR THE QUARTER ENDED ON 30-6-2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 31-07-2025Jul 31, 2025
Jul 31, 2025Board Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations 2015.Jul 14, 2025
Jul 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Declaration Of Non-Applicability Of Reg. 32 Of The SEBI (LODR) Regulations 2015 (Statement Of Deviation Or Variation For Proceeds Of Public Issue Rights Issue Preferential Issue QIP) For The Quarter Ended 30.06.2025.
Jul 02, 2025
Jul 02, 2025Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulation 2015) For The Quarter Ended 30-6-2025.Jul 02, 2025
Jul 02, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 17, 2025
May 17, 2025Integrated Filing (Financial)May 16, 2025
May 16, 2025Board Meeting Outcome for Outcome Of The Board MeetingMay 16, 2025
May 16, 2025Outcome Of The Board MeetingMay 16, 2025
May 16, 2025Board Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations 2015.May 07, 2025
May 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Apr 07, 2025Confirmation Of Not Being Identified As Large Corporate In Terms Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26 2018 - Fund Raising By Issuance Of Debt Securities By Large EntitiesApr 03, 2025
Apr 03, 2025Non - Applicability Of Annual Secretarial Compliance Report Under Regulation 24A Of SEBI (LODR) Regulations 2015 (As Amended) Read With SEBI Circular No. CIR/CFD/CMD1/27/2019 Dated 8Th February 2019 BSE Circular Nos. LIST/COMP/10/2019-20 Dated 9Th May 201Apr 03, 2025
Apr 03, 2025Annual Disclosure Of Encumberances Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulation 2011 For The Year Ended 31St March 2025Apr 03, 2025
Apr 03, 2025Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulation 2015).Apr 02, 2025
Apr 02, 2025Declaration Of Non-Applicability Of Reg. 32 Of The SEBI (LODR) Regulations 2015 (Statement Of Deviation Or Variation For Proceeds Of Public Issue Rights Issue Preferential Issue QIP) For The Quarter Ended 31.03.2025.
Apr 02, 2025
Apr 02, 2025Closure of Trading WindowMar 29, 2025
Mar 29, 2025Integrated Filing (Financial)Mar 04, 2025
Mar 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2025
Feb 01, 2025Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015Jan 31, 2025
Jan 31, 2025Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015Jan 31, 2025
Jan 31, 2025Technical Indicators
RSI(14)
Neutral 45.66
ATR(14)
Volatile 3.37
STOCH(9,6)
Neutral 36.55
STOCH RSI(14)
Neutral 26.86
MACD(12,26)
Bearish -0.21
ADX(14)
Weak Trend 12.41
UO(9)
Bearish 35.14
ROC(12)
Downtrend And Accelerating -4.98
WillR(14)
Neutral -70.81
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
